168 related articles for article (PubMed ID: 23442605)
1. Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
Bi FF; Li D; Yang Q
BMC Cancer; 2013 Feb; 13():90. PubMed ID: 23442605
[TBL] [Abstract][Full Text] [Related]
2. A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
Li D; Bi FF; Chen NN; Cao JM; Sun WP; Zhou YM; Li CY; Yang Q
Cell Cycle; 2014; 13(21):3442-9. PubMed ID: 25485588
[TBL] [Abstract][Full Text] [Related]
3. Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
Li D; Bi FF; Cao JM; Cao C; Li CY; Liu B; Yang Q
Oncotarget; 2014 Jan; 5(1):291-7. PubMed ID: 24448423
[TBL] [Abstract][Full Text] [Related]
4. Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer.
Bi FF; Li D; Yang Q
Biomed Res Int; 2013; 2013():946268. PubMed ID: 23762867
[TBL] [Abstract][Full Text] [Related]
5. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Gan A; Green AR; Nolan CC; Martin S; Deen S
Hum Pathol; 2013 Aug; 44(8):1638-47. PubMed ID: 23574784
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid receptor repression mediated by BRCA1 inactivation in ovarian cancer.
Fang YY; Li D; Cao C; Li CY; Li TT
BMC Cancer; 2014 Mar; 14():188. PubMed ID: 24629067
[TBL] [Abstract][Full Text] [Related]
7. Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose) polymerase-1-mediated epigenetic mechanism.
Nocchi L; Tomasetti M; Amati M; Neuzil J; Santarelli L; Saccucci F
J Biol Chem; 2011 Jun; 286(22):19478-88. PubMed ID: 21489980
[TBL] [Abstract][Full Text] [Related]
8. Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity.
Zampieri M; Passananti C; Calabrese R; Perilli M; Corbi N; De Cave F; Guastafierro T; Bacalini MG; Reale A; Amicosante G; Calabrese L; Zlatanova J; Caiafa P
PLoS One; 2009; 4(3):e4717. PubMed ID: 19262751
[TBL] [Abstract][Full Text] [Related]
9. Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer.
Li D; Bi FF; Cao JM; Cao C; Li CY; Yang Q
J Exp Clin Cancer Res; 2013 Dec; 32(1):102. PubMed ID: 24321281
[TBL] [Abstract][Full Text] [Related]
10. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
11. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
12. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
13. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.
May T; Yang J; Shoni M; Liu S; He H; Gali R; Ng SK; Crum C; Berkowitz RS; Ng SW
Neoplasia; 2013 Jun; 15(6):600-8. PubMed ID: 23730208
[TBL] [Abstract][Full Text] [Related]
15. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Moschetta M; George A; Kaye SB; Banerjee S
Ann Oncol; 2016 Aug; 27(8):1449-55. PubMed ID: 27037296
[TBL] [Abstract][Full Text] [Related]
16. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
17. Regulation of HFE expression by poly(ADP-ribose) polymerase-1 (PARP1) through an inverted repeat DNA sequence in the distal promoter.
Pelham C; Jimenez T; Rodova M; Rudolph A; Chipps E; Islam MR
Biochim Biophys Acta; 2013 Dec; 1829(12):1257-1265. PubMed ID: 24184271
[TBL] [Abstract][Full Text] [Related]
18. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Zhang Z; Dou X; Yang H; Jia L; Qin K; Gao X; Yang B; Zhang W; Qin C; Zhang F; Shan B
Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
[TBL] [Abstract][Full Text] [Related]
19. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
20. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
